As of May 27
| +0.36 / +0.79%|
The 8 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 63.50, with a high estimate of 96.00 and a low estimate of 57.00. The median estimate represents a +37.48% increase from the last price of 46.19.
The current consensus among 9 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.